CLINUVEL Pharmaceuticals (ASX:CUV) has presented new evidence of its lead therapy SCENESSE (afamelanotide) delivering visible and lasting repigmentation in patients with vitiligo, one of the world’s most common pigmentary disorders.
CLINUVEL’s SCENESSE demonstrates promising results in vitiligo patients
September 21, 2025 Australian Biotech
Latest Video
New Stories
-
Orthocell boosts balance sheet with capital raise to drive nerve repair product growth
October 19, 2025 - - Australian Biotech -
Amplia targets US market expansion as FAK inhibitor shows promise in pancreatic cancer
October 19, 2025 - - Australian Biotech -
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - - Latest News -
AdvanCell unveils promising first clinical results for 212Pb-ADVC001 in prostate cancer
October 19, 2025 - - Australian Biotech -
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - - Latest News -
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - - Latest News -
The 'Dispatched' Week in Review Podcast - 17 October
October 17, 2025 - - Podcast